In a significant milestone for pediatric oncology research, Indian researchers have established one of the country's largest childhood cancer survivorship cohorts, providing new insights into the long-term outcomes of children who have successfully completed cancer treatment.

Eisai has announced a significant investment in its manufacturing facility in Hatfield, United Kingdom, aimed at expanding its capabilities for medicines that require specialized cold-chain storage and transportation. The project is being supported by the UK Government through the Life Sciences Innovative Manufacturing Fund (LSIMF).

In a major step toward strengthening international regulatory cooperation, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA) have announced a new liaison programme designed to deepen collaboration between the two agencies. The initiative was unveiled during the DIA Global Annual Meeting in Philadelphia by MHRA Chief Executive Lawrence Tallon and FDA Deputy Commissioner Grace Graham.

Eli Lilly has provided new insights into retatrutide, its investigational medicine that is attracting significant attention for its potential to treat obesity, type 2 diabetes, and several obesity-related health conditions. While the therapy remains under clinical development and is not yet approved for public use, ongoing research suggests it could become one of the most impactful treatments in the rapidly growing obesity care market.